PA
AKRO

Perceptive Advisors’s Akero Therapeutics AKRO Stock Holding History

Perceptive Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,135,766
Closed -$53.9M – 117
2025
Q3 		$53.9M Buy
1,135,766
+219,879
+24% +$10.6M 1.56% 22
2025
Q2 		$48.9M Buy
915,887
+122,927
+16% +$5.59M 1.81% 15
2025
Q1 		$32.1M Sell
792,960
-392,632
-33% -$16.6M 1.13% 26
2024
Q4 		$33M Sell
1,185,592
-529,214
-31% -$16M 0.91% 30
2024
Q3 		$49.2M Buy
1,714,806
+214,909
+14% +$5.6M 1.04% 30
2024
Q2 		$35.2M Buy
1,499,897
+112,426
+8% +$2.4M 0.85% 36
2024
Q1 		$35M Buy
1,387,471
+419,696
+43% +$10.1M 0.61% 50
2023
Q4 		$22.6M Sell
967,775
-651,650
-40% -$12.9M 0.5% 48
2023
Q3 		$81.9M Sell
1,619,425
-321,250
-17% -$15M 2.73% 8
2023
Q2 		$90.6M Buy
1,940,675
+1,417,150
+271% +$64.9M 2.62% 11
2023
Q1 		$20M Buy
523,525
+173,000
+49% +$7.71M 0.59% 45
2022
Q4 		$19.2M Sell
350,525
-79,475
-18% -$3.41M 0.54% 44
2022
Q3 		$14.6M Buy
+430,000
New +$6.58M 0.42% 54
2020
Q4 		– Sell
-21,938
Closed -$675K – 140
2020
Q3 		$675K Buy
+21,938
New +$767K 0.01% 121

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Perceptive Advisors's AKRO Position: Q4 2025 in Review

Perceptive Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,135,766 shares — an estimated $53.9M sold.

Perceptive Advisors first reported a position in AKRO in Q3 2020 and held it in 14 quarters. The position peaked at $90.6M in Q2 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Perceptive Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Perceptive Advisors sold 1,135,766 Akero Therapeutics shares in Q4 2025, an estimated $53.9M.
  • Perceptive Advisors first reported a position in Akero Therapeutics in Q3 2020 and held it in 14 quarters.
  • Perceptive Advisors's Akero Therapeutics position peaked at $90.6M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Perceptive Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.